PLANTATION, Fla., Nov. 22 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA; VRA.U) today announced that, commencing at the opening of
trading on Tuesday, November 28, 2006, holders of Viragen's Units may
voluntarily separate the Units into their component common stock and
warrants. Upon separation, the common stock and warrants comprising the
Units may be traded separately from the Units. Unit holders may also elect
to continue to hold or trade their Units intact.
Viragen's common stock trades on the American Stock Exchange (Amex)
under the symbol "VRA" and commencing at the opening of trading on November
28, 2006, the warrants will trade on the Amex under the symbol "VRA.WS".
The Units have traded under the symbol "VRA.U" since October 31, 2006,
following the effective date of Viragen's underwritten public offering,
with each Unit consisting of one share of common stock and one warrant to
purchase one share of common stock, exercisable at a price of $.31 per
share until the warrants' expiration on October 29, 2011.
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are
a bio-pharmaceutical company engaged in the research, development,
manufacture and commercialization of therapeutic proteins for the treatment
of cancers and viral diseases. Our product and product candidate portfolio
includes: Multiferon(R) (multi-subtype, human alpha interferon) uniquely
positioned in valuable niche indications, such as high-risk malignant
melanoma, other niche cancer indications and selected infectious diseases;
VG101, a humanized monoclonal antibody that binds selectively to an antigen
over-expressed on Stage IV malignant melanoma tumors; and VG102, a highly
novel humanized monoclonal antibody that binds selectively to an antigen
that is over- expressed on nearly all solid tumors. We are also pioneering
the development of the OVA(TM) System (Avian Transgenics), with the
renowned Roslin Institute, the creators of "Dolly the Sheep", as a
revolutionary manufacturing platform for the large-scale, efficient and
economical production of human therapeutic proteins and antibodies, by
expressing these products in the egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the Company's ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general.
Forward-looking statements speak only as to the date they are made. The
Company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or Fax, +1-954-233-1414, or
dcalder@viragen.com
|
